American College of Cardiology Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with T2D and Atherosclerotic Cardiovascular Disease In 2018, the American College of Cardiology (ACC) published an expert consensus decision pathway on the use of novel therapies, namely GLP-1 RAs and SGLT-2 inhibitors, to reduce cardiovascular risk in patients with T2D
For broader context on what GLP-1 medications do to your cholesterol and lipid panel over time, the article on GLP-1 medications and cholesterol walks through what to expect in your lab results at different treatment milestones
You have a history of any hormone-sensitive condition, or active cancer Neither is appropriate without specialist evaluation
What other tools do we have for you
"We've really seen how, how much weight loss makes a difference in this patient population, and how badly these patients are struggling." Young girls are particularly at risk for complications from obesity and type 2 diabetes, according to experts including Dr
Wellness is a personal journey, and what works for one person may need adjustment for another
